Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-141 plus nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer
2014-004572-34Phase 2Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Aug 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Istiratumab + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoint: Progression-free survival. Started Aug 2015; status: terminated.
02
Drugs
istiratumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2014-004572-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004572-34.